Volume 8, Number 4—April 2002
Research
Laboratory Reporting of Staphylococcus aureus with Reduced Susceptibility to Vancomycin in United States Department of Veterans Affairs Facilities1
Table 2
Susceptibility to selected gram-positive agents of isolates of reported Staphylococcus aureus with reduced susceptibility to vancomycin from United States Veterans Health Administration medical facilities, FFY 1999a
Case | Beta-lactamase | MIS/sensitivity status | |||||||
---|---|---|---|---|---|---|---|---|---|
oxacillin | imipenem | rifampin | TMP/SMX | erythromycin | TCN | clindamycin | chloramphenicol | ||
1 | negative | /R | /S | /R | /S | /R | |||
2 | positive | <0.5 μg/mL | <4 μg/mL | <1 μg/mL | <2 μg/mL | =0.5 μg/mL | <2 μg/mL | <0.25 μg/mL | |
3 | positive | >2 μg/mL | >8 μg/mL/R | <1 μg/mL | <2 μg/mL | >4 μg/mL/R | <2 μg/mL | >2 μg/mL/R | |
4 | positive | >4 μg/mL | >8 μg/mL/R | <1 μg/mL | <2 μg/mL | >4 μg/mL/R | <2 μg/mL | >2 μg/mL/R | |
5 | positive | <0.5 μg/mL/S | >8 μg/mL/R | >2 μg/mL/R | <2/38 μg/mL/S | >8 μg/mL/R | >2 μg/mL/R | ||
6 | positive | >2 μg/mL/R | 2 μg/mL/R | >1 μg/mL/S | <2/38 μg/mL/S | >4 μg.mL/R | <2 μg/mL/S | 8 μg/mL/S | |
7 | positive | >2 μg/mL/R | >8 μg/mL/R | >2 μg/mL/R | >2/38 μg/mL/R | >4 μg/mL/R | >8 μg/mL/R | 16 μg/mL/I | |
8 | positive | >2 μg/mL/R | >8 μg/mL/R | >1 μg/mL/S | <2/38 μg/mL/S | >4 μg/mL/R | <2 μg/mL/S | >2 μg/mL/R | 16 μg/mL/I |
9 | positive | >2 μg/mL/R | <1 μg/mL/S | <2 μg/mL/S | >4 μg/mL/R | <2 μg/mL/S | >2 μg/mL/R | ||
10 | negative | <0.5 μg/mL/S | <1 μg/mL/S | <2 μg/mL/S | <0.25 μg/mL/S | <2 μg/mL/S | =0.5 μg/mL/S | ||
11 | positive | <0.5 μg/mL/S | <1 μg/mL/S | <2 μg/mL/S | >4 μg/mL/R | <2 μg/mL/S | <0.25 μg/mL/S | ||
12 | positive | >2 μg/mL/R | <1 μg/mL/S | <2 μg/mL/S | >4 μg/mL/R | <2 μg/mL/S | >2 μg/mL/R | ||
13 | positive | <0.5 μg/mL/S | <1 μg/mL/S | <2 μg/mL/S | >4 μg/mL/R | >8 μg/mL/R | >2 μg/mL/R | ||
14 | positive | >2 μg/mL/R | >2 μg/mL/R | <2 μg/mL/S | >4 μg/mL/R | <2 μg/mL/S | >2 μg/mL/R | ||
15 | /R | <2 μg/mL/S | /R | <2 μg/mL/S | <2 μg/mL/S | =8 μg/mL/S | |||
16 | 1 μg/mL/S | <2/38 μg/mL/S | 0.5 μg/mL/S | >2 μg/mL/R | |||||
17 | >4 μg/mL/R | <2/38 μg/mL/S | >4 μg/mL/R | >2 μg/mL/R | |||||
18 | positive | <0.05 μg/mL | <4 μg/mL | <1 μg/mL | <2 μg/mL | <0.25 μg/mL | <2 μg/mL | 0.5 μg/mL | |
19 | positive | >8 μg/mL/R | >4 μg/mL/R | <16 μg/mL/S | >8 μg/mL/R | >16 μg/mL/R | >8 μg/mL/R | ||
Totalb | 14/16=pos | 12/19 =R | 6/8=R | 4/15=R | 1/19=R | 14/18=R | 4/17=R | 12/17=R | 0/4=R |
aFFY=Federal fiscal year; S=susceptible, I=intermediate and R=resistant based on laboratory interpretative criteria.
bThe authors took the liberty of placing interpretation on some reported MIC values that did not have an interpretation of S, I, or R on information provided from the facility.
1A portion of this material was presented at the 11th Annual Scientific Meeting of the Society for Healthcare Epidemiology of America in Toronto, Ontario, Canada (Abstract #49), April 2001.